Trevena Inc (NASDAQ:TRVN) saw strong trading volume on Friday . 1,798,098 shares traded hands during trading, an increase of 81% from the previous session’s volume of 994,718 shares.The stock last traded at $1.63 and had previously closed at $1.51.
Several equities research analysts recently weighed in on the stock. HC Wainwright cut their target price on shares of Trevena from $8.00 to $7.00 and set a “buy” rating on the stock in a research note on Thursday, October 12th. Barclays downgraded shares of Trevena from an “overweight” rating to an “equal weight” rating and cut their target price for the stock from $15.00 to $2.50 in a research note on Monday, October 16th. Oppenheimer set a $5.00 target price on shares of Trevena and gave the stock a “buy” rating in a research note on Thursday, October 12th. Zacks Investment Research raised shares of Trevena from a “hold” rating to a “buy” rating and set a $2.50 target price on the stock in a research note on Wednesday, October 18th. Finally, Needham & Company LLC cut their target price on shares of Trevena from $9.00 to $7.00 and set a “buy” rating on the stock in a research note on Wednesday, November 8th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and eight have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $7.35.
The company has a debt-to-equity ratio of 0.38, a quick ratio of 4.92 and a current ratio of 4.92. The firm has a market capitalization of $90.14, a PE ratio of -0.99 and a beta of -0.51.
Trevena Company Profile
Trevena Inc is a biopharmaceutical company, which is engaged in developing various therapies. The Company is developing OLINVO, a u-receptor G protein pathway selective modulator (u-GPS) for the management of moderate-to-severe acute pain where intravenous (IV) administration is preferred. It is focused on commercializing it in the United States for use in acute care settings, such as hospitals and ambulatory surgery centers.
Receive News & Ratings for Trevena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena and related companies with MarketBeat.com's FREE daily email newsletter.